Brilacidin

February 27, 2017

Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial

News

Cellceutix says the ongoing Phase 2 clinical trial of its lead drug candidate Brilacidin has progressed to its third cohort (highest dose) to induce remission of mild-to-moderate ulcerative colitis, now that the study’s Safety Committee has ... Read more

January 18, 2017

Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin

News

Cellceutix has completed enrolling a second cohort of patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), two forms of inflammatory bowel disease (IBD), in its Phase 2 clinical trial evaluating brilacidin (PMX-30063). ... Read more

December 9, 2016

Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis

News

Cellceutix has initiated the dose escalation of brilacidin (PMX-30063) in the second cohort of patients enrolled in a Phase 2 clinical trial evaluating the drug candidate for the treatment of ulcerative ... Read more

June 21, 2016June 21, 2016

Cellceutix Begins Phase 2 Trial of Ulcerative Proctitis Drug Candidate Brilacidin

Crohn's Disease, IBD News, News, Ulcerative colitis

Cellceutix recently began screening participants and administering therapy for its Phase 2 trial assessing the drug candidate Brilacidin for the treatment of ulcerative proctitis, a mild form of ulcerative colitis. The causes for ... Read more